 Context Therapeutics NASDAQ:CNTX Inc and The Menarini Group have announced a clinical trial collaboration and supply agreement for Menarinis oral selective estrogen receptor degrader SERD, elacestrant. The womens oncology company said the agreement will support the upcoming Phase 1b2 ELONA clinical proof-of-concept trial evaluating onapristone extended release ONA-XR, an oral progesterone receptor PR antagonist, in combination with elacestrant in estrogen receptor positive ER, PR HER2- metastatic breast cancer mBC patients who have previously been treated with a CDK46 inhibitor. 